849 related articles for article (PubMed ID: 25428711)
1. Ferric carboxymaltose: a review of its use in iron deficiency.
Keating GM
Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
[TBL] [Abstract][Full Text] [Related]
2. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
3. Ferric Carboxymaltose: A Review in Iron Deficiency.
Scott LJ
Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
[TBL] [Abstract][Full Text] [Related]
4. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
5. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
10. [Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].
Češka R
Vnitr Lek; 2014 Dec; 60(12):1033-9. PubMed ID: 25692829
[TBL] [Abstract][Full Text] [Related]
11. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
Qunibi WY; Martinez C; Smith M; Benjamin J; Mangione A; Roger SD
Nephrol Dial Transplant; 2011 May; 26(5):1599-607. PubMed ID: 20929915
[TBL] [Abstract][Full Text] [Related]
13. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
[TBL] [Abstract][Full Text] [Related]
18. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE; Angerosa M
Drug Des Devel Ther; 2014; 8():2475-91. PubMed ID: 25525337
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Breymann C; Gliga F; Bejenariu C; Strizhova N
Int J Gynaecol Obstet; 2008 Apr; 101(1):67-73. PubMed ID: 18234203
[TBL] [Abstract][Full Text] [Related]
20. A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
Montandon SV; Fajt ML; Petrov AA
Curr Drug Saf; 2016; 11(2):145-8. PubMed ID: 26647917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
